Astellas strikes infectious disease antibody deal with Evec
This article was originally published in Scrip
Astellas has licensed in a still preclinical stage antibody from the Japanese bioventure Evec which it is looking to develop against a range of infectious diseases.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.